Zura Bio Limited
ZURAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeZura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. Valued at $322.0M, ZURA is a small-cap name in its sector. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Market Cap
$322.0M
Beta
0.01
P/E (TTM)
—
P/E (Fwd)
-4.87
EPS (TTM)
$-1.12
EPS (Fwd)
$-0.69
ROE
-51.0%
ROA
-31.2%
Cash
$205.1M
Total Debt
$0
Free CF
-$48.8M
52W Change
-14.5%
Annual Financials
Cash vs Debt
Where ZURA stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, ZURA finished 22.03% below its 150-day moving average ($5.13) and 24.81% below its 200-day moving average ($5.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZURA overbought or oversold?
At the October 12, 2026 close, ZURA's RSI(14) was 32.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zura Bio Limited reports $205.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$48.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -51.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
ZURA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZURA.